GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹109 Cr | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹109 Cr |
| Mar2024 | ₹-357 Cr |
| Mar2023 | ₹2,621 Cr |
| Mar2022 | ₹1,270 Cr |
| Mar2021 | ₹2,804 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹109 Cr | Positive | |
| Mar2024 | ₹-357 Cr | Negative | |
| Mar2023 | ₹2,621 Cr | 106.48 | |
| Mar2022 | ₹1,270 Cr | -54.72 | |
| Mar2021 | ₹2,804 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹63,754.6 Cr | -3.5% | 0.8% | 66.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹442,725.0 Cr | -3.2% | 10.5% | 9.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹182,775.0 Cr | 0.8% | 9.5% | 4.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹151,764.0 Cr | 2% | 9.9% | 35.4% | Stock Analytics | |
| CIPLA | ₹113,007.0 Cr | -1.9% | 13.3% | -6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,098.0 Cr | -1.8% | 7.4% | 8.2% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -3.5% |
0.8% |
66.2% |
| SENSEX | 0.2% |
-4.9% |
-8.4% |
You may also like the below Video Courses